Infliximab treatment for resistant Achilles tendonitis

Authors

• Said M. Al-Asfar, North West Armed Forces Hospital, Department of Internal Medicine, Division of Rheumatology, PO Box 100, Tabuk, Kingdom of Saudi Arabia. Tel. +966 506721398. Fax. +966 (4) 4411056. E-mail: salasfar{at}hotmail.com
• Mohammad Attar, North West Armed Forces Hospital, Department of Internal Medicine, Division of Rheumatology, PO Box 100, Tabuk, Kingdom of Saudi Arabia. Tel. +966 506721398. Fax. +966 (4) 4411056. E-mail: salasfar{at}hotmail.com
• Hasan Shacfeh, North West Armed Forces Hospital, Department of Internal Medicine, Division of Rheumatology, PO Box 100, Tabuk, Kingdom of Saudi Arabia. Tel. +966 506721398. Fax. +966 (4) 4411056. E-mail: salasfar{at}hotmail.com

Abstract

Undifferentiated spondyloarthropathies USPA can sometimes be refractory to usual disease modifying agents. Anti-tumor necrosis factor TNF-alpha agents have been shown to be effective in spondyloarthropathies. Few articles described the efficacy of TNF-alpha antagonists in USPA. Our patient had refractory Achilles tendonitis as an early manifestation of USPA which responded dramatically to infliximab treatment.

Article Type

Case Report

First Page

1228

Last Page

1230

Recommended Citation

Al-Asfar, Said M.; Attar, Mohammad; and Shacfeh, Hasan (2009) "Infliximab treatment for resistant Achilles tendonitis," Saudi Medical Journal: Vol. 30: Iss. 9, Article 19.
DOI: https://doi.org/10.15537/1658-3175.4835